Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer

Myung-Ju Ahn


Stage III non-small cell lung cancer (NSCLC) accounts for one-third of NSCLC patients. Stage IIIA is considered resectable, but most of stage IIIA/B patients are unresectable, leading to chemoradiotherapy being standard of care. The median overall survival remains poor with less than 15% of 5-year overall survival after chemoradiotherapy.

Download Citation